Prognostic factors in advanced ovarian cancer

International Journal of Gynecological Cancer

Volumn 7, Issue SUPPL. 1, 1997, Pages 4-8

  Cervantes, A ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Ovarian cancer; Prognostic factors

Indexed keywords

CA 125 ANTIGEN; CARBOHYDRATE ANTIGEN; COLONY STIMULATING FACTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR; HEAT SHOCK PROTEIN 60; ONCOPROTEIN;

ADVANCED CANCER; AGING; CANCER GRADING; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CONFERENCE PAPER; FEMALE; HUMAN; ONCOGENE C ERB; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS;

EID: 0030818014     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.7.s1.3.x     Document Type: Conference Paper

References (38)

1. Simon R, Altman DG. Statistical aspects of prognostic factors studies in oncology. Br J Cancer 1994; 69: 979-85.
2. Levine MN, Browman GP, Gent M, et al. When is a prognostic factor useful? A guide for the perplexed. J Clin Oncol 1991; 9: 348-56.
3. Levin L, Lund B, Heintz APM. An overview of multivariate analyses of prognostic variables with special reference to the role of cytoreductive surgery. Ann Oncol 1993; 4 (Suppl. 4): 23-9.
4. Swenerton KD, Hislop TG, Spinelli J, et al. Ovarian carcinoma: A multivariate analysis of prognostic factors. Obstet Gynecol 1985; 64: 264-70.
5. Redman JR, Petroni GR, Saigo P, et al. Prognostic factors in advanced ovarian carcinoma. J Clin Oncol 1986; 4: 515-23.
6. Blumenfield D, Braly PS, Ben-Ezra J, et al. Tumor DNA content as a prognostic feature in advanced ovarian carcinoma. Gynecol Oncol 1987; 27: 389-98.
7. Rodenburg CJ, Cornelisse CJ, Heints APM, et al. Tumor ploidy as a major prognostic factor in advanced ovarian cancer. Cancer 1987; 59: 317-23.
8. Friedlander ML, Hedley DC, Swanson C, et al. Prediction of long term survival by flow cytometric analysis of cellular DNA content in patients with advanced ovarian cancer. J Clin Oncol 1988; 6: 282-90.
9. Creasman WT, Omura GA, Brady MF, et al. A randomized trial of cyclophosphamide, doxorubicin and cisplatin with or without bacillus Calmette-Guerin in patients with suboptimal stage II and IV ovarian cancer: A Gynecologic Oncology Group study. Gynecol Oncol 1990; 39: 239-43.
10. Hunter RW, Alexander NDE, Soutter WP. Meta-analysis of surgery in advanced ovarian carcinoma. Is maximum cytoreductive surgery an independent determinant of prognosis? Am J Obstet Gynecol 1992; 166: 504-11.
11. Warwick J, Kehoe S, Earl H, et al. Long term follow-up of patients with advanced ovarian cancer treated in randomised clinical trials. Br J Cancer 1995; 72: 1513-17.
12. Griffiths CTH. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Symposium on ovarian cancer. Natl Cancer Inst Monographs 1975; 42: 1010-14.
13. Heintz APM. Surgery in advanced ovarian carcinoma. Is there proof to show the benefit? Eur J Surg Oncol 1988; 14: 91-9.
14. Lund B, Wiliamson P. Prognostic factors for overall survival in patients with advanced ovarian carcinoma. Ann Oncol 1991; 2: 281-7.
15. Bertelsen K, Holund B, Andersen E. Reproducibility and prognostic value of histologic type and grade in early epithelial ovarian cancer. Int J Gynecol Cancer 1993; 3: 72-9.
16. Sevelda P, Vavra N, Schemper M, Salzer H. Prognostic factors for survival in stage I epithelial ovarian carcinoma. Cancer 1990; 65: 2349-52.
17. Rubin S, Hoskins W, Saigo P, et al. Prognostic factors for recurrence following negative second look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy. Gynecol Oncol 1991; 42: 137-41.
18. Aure JC, Hoes K, Kolstad P. Clinical and histological studies of ovarian carcinoma. Obstet Gynecol 1971; 37: 1-9.
19. Kallioniemi OP, Punnonen R, Mattila J, et al. Prognostic significance of DNA index, multiploidy and S-phase fraction in ovarian cancer. Cancer 1988; 61: 334-9.
20. Conte PF, Alama A, Rubagotte A, et al. Cell kinetics in ovarian cancer. Relationship to clinicopathologic features, responsiveness to chemotherapy and survival. Cancer 1989; 64: 1188-91.
21. Baak JPA, Schipper NW, Wisse-Brekelmans ECM, et al. The prognostic value of morphometrical features and cellular DNA content in cisplatin-treated late ovarian cancer patients. Br J Cancer 1988; 57: 503-8.
22. van Howelingen JC, ten Bokkel Huinink WW, van der Berg MEL, et al. Predictability of the survival of patients with advanced ovarian cancer. J Clin Oncol 1989; 7: 769-73.
23. Slotman B, Nauta J, Rao BR. Survival of patients with ovarian cancer. Cancer 1990; 66: 740-4.
24. Bizzi A, Codegoni AM, Landoni F, et al. Steroid receptors in epithelial ovarian carcinoma: Relation to clinical parameters and survival. Cancer Res 1988; 48: 6222-6.
25. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-12.
26. Berchuck A, Kamel A, Whitaker R, et al. Overexpression of HER-2/neu is associated with poor survival in epithelial ovarian cancer. Cancer Res 1990; 50: 4087-91.
27. Scambia G, Ferrandina G, Marone M, et al. nm23 in ovarian cancer: Correlation with clinical outcome and other clinico-pathologic and biochemical prognostic parameters. J Clin Oncol 1996; 14: 334-42.
28. Izquierdo MA, van der Zee AGJ, Vermorken JB, et al. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst 1995; 87: 1230-7.
29. Dittrich C, Dittrich E, Sevelda P, et al. Clonogenic growth in vitro: An independent biologic prognostic factor in ovarian carcinoma. J Clin Oncol 1991; 9: 381-8.
30. Bast RC, Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Eng J Med 1983; 309: 883-7.
31. Lavin PT, Knapp RC, Malkasian G, et al. CA 125 for the monitoring of ovarian carcinoma during primary therapy. Obstet Gynecol 1987; 69: 223-7.
32. Hawkins RE, Roberts K, Wiltshaw E, et al. The prognostic significance of the half-life of serum CA125 in patients responding to chemotherapy for epithelial ovarian carcinoma. Br J Obstet Gynaecol 1989; 96: 1395-9.
33. Hunter VJ, Daly L, Helms M, et al. The prognostic significance of CA125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. Am J Obstet Gynecol 1990; 163: 1164-9.
34. van der Burg MEL, Lammes FB, van Putten WLJ, Stoter G. Ovarian cancer: The prognostic value of serum half-life of CA125 during induction chemotherapy. Gynecol Oncol 1988; 30: 307-12.
35. Rustin GJS, Nelstrop A, Stilwell MA, et al. Use of CA125 to predict survival of patients with ovarian carcinoma. J Clin Oncol 1989; 7: 1667-71.
36. Rustin GJS, Nelstrop A, McClean P, et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA125. J Clin Oncol 1996; 14: 1545-51.
37. Rustin GJS, Nelstrop A, Tuxen MK, et al. Defining progression of ovarian cancer during follow-up according to CA125: A North Thames Ovary group. Ann Oncol 1996; 7: 361-4.
38. Frasci G, Conforti S, Zullo F, et al. A risk model for ovarian carcinoma patients using CA125. Cancer 1996; 77: 1122-30.